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Synucleins are involved in multiple steps of the neurotransmitter turnover, but the largely normal
synaptic function in young adult animals completely lacking synucleins suggests their roles are
dispensable for execution of these processes. Instead, they may be utilized for boosting the efﬁciency of
certain molecular mechanisms in presynaptic terminals, with a deﬁciency of synuclein proteins sensi-
tizing to or exacerbating synaptic malfunction caused by accumulation of mild alterations, which are
commonly associated with aging. Although functional redundancy within the family has been reported,
it is unclear whether the remaining synucleins can fully compensate for the deﬁciency of a lost family
member or whether some functions are speciﬁc for a particular member. We assessed several structural
and functional characteristics of the nigrostriatal system of mice lacking members of the synuclein family
in every possible combination and demonstrated that stabilization of the striatal dopamine level
depends on the presence of a-synuclein and cannot be compensated by other family members, whereas
b-synuclein is required for efﬁcient maintenance of animal’s balance and coordination in old age.
 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Among several proteins whose malfunction has been linked to
molecular events leading to neuronal dysfunction in Parkinson’s dis-
ease (PD), a-synuclein deservingly hold the status of a primary culprit
due to its causative role in certain familial formsandapivotal role in the
formationofhistopathologicalhallmarks inboth familial and idiopathic
forms of the disease [reviewed in (Dev et al., 2003; Venda et al., 2010)].
Moreover, polymorphismswithin the locus encoding a-synuclein have
been found to be associatedwith the increased risk of PD development
(Kay et al., 2008;Mizuta et al., 2008; Pankratz et al., 2009; Scholz et al.,Cardiff University, Sir Martin
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er Inc. This is an open access artic2009; Sutherland et al., 2009), with recent studies suggesting that
disease progression to the symptomatic stage correlates with the
spreading of pathologic a-synuclein aggregates to dopaminergic neu-
rons of the substantia nigra pars compacta (SNpc) (Braak et al., 2006;
Desplats et al., 2009; Luk et al., 2012; Recasens et al., 2014).
Aggregation of a-synuclein not only generates various products
intrinsically toxic for neurons but also depletes the pool of func-
tional a-synuclein, particularly in presynaptic terminals, its normal
site of localization and function. The importance of a-synuclein for
the efﬁcient function of vertebrate presynaptic neurotransmitter
storage and release machinery has been demonstrated in experi-
ments with live animals or primary neurons derived from either
animals overexpressing various forms a-synuclein or depleted of
endogenous a-synuclein by targeted inactivation of Snca, gene
encoding mouse a-synuclein (Abeliovich et al., 2000; Cabin et al.,
2002; Chandra et al., 2004, 2005; Janezic et al., 2013; Lim et al.,
2010; Lin et al., 2012; Nemani et al., 2010; Senior et al., 2008;
Taylor et al., 2014; Yavich et al., 2004, 2005, 2006).
However, in models with transgenic a-synuclein expression, it is
problematic to identify the chain of events leading to alterations of
synaptic functions. A modiﬁed or overexpressed exogenous a-syn-
uclein may hijack and compromise the endogenous a-synucleinle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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novel gain-of-function effects of the exogenous a-synuclein, which
can be completely unrelated to any of normal functions of the
endogenous protein or affect them only indirectly. On the other
hand, interpretation of experimental data obtained in a-synuclein
null mutant mice is complicated by the expression in vertebrate
neurons, including dopaminergic neurons of SNpc, of 2 closely
related members of the synuclein family, b-synuclein and g-synu-
clein. These 2 proteins are not known to be directly involved in
etiology or pathogenesis of PD but can function in the same molec-
ular processes in neuronal synapses as a-synuclein and therefore,
compensate, at least partially, for its loss. This functional redundancy
might mask consequences of a-synuclein depletion in the SNpc of
null mutant mice.
In the absence of the interfamily compensation, that is,
following inactivation of all 3 synuclein-encoding genes, animals
develop more pronounced behavioral, physiological, and
biochemical changes in their nervous system, including the
nigrostriatal axis, than animals with null mutations for 1 or 2 of
these genes. Importantly, synaptic malfunction develops gradually
and its manifestations become detectable only in aging triple
synuclein null mutant mice (Anwar et al., 2011; Burre et al., 2010;
Greten-Harrison et al., 2010). These observations suggest that the
presence of synucleins delays functional decline of neuronal
synapses in the aging nervous system. However, the impact of each
family member on this process might be different. Indeed, a
signiﬁcant, although not sufﬁcient to cause functional alterations,
decrease of striatal dopamine level has been observed only in adult
a/b-synuclein double and aged a-synuclein but not in adult a/g-
synuclein double and aged g-synuclein null mutantmice (Al-Wandi
et al., 2010; Chandra et al., 2004; Robertson et al., 2004).
For synucleins, as any other proteins that affect efﬁciency rather
than execution or robust regulation of intracellular processes, it is
particularly important to consider effects of external factors when
comparing data obtained in different setups. In particular, for
studies of mice lacking such proteins, genetic background and
environmental conditions might signiﬁcantly affect experimental
data, and at least some discrepancies in results obtained in similar
studies of synuclein null mutant mice carried out in different
laboratories may have been caused by differences in these
parameters.
Therefore, to address the role of each member of the synuclein
family in maintaining the efﬁciency of the nigrostriatal system
function in aged animals, we carried out a breeding programme
aimed to produce mouse lines lacking 1, 2, or all 3 synucleins and
control wild-type mice, on the same C57Bl6/J genetic background,
and systematically studiedmotor behavior andmajor parameters of
the nigrostriatal system in cohorts of aged mice of all 8 genotypes.
2. Material and methods
2.1. Generation of double and triple synuclein null mutant animals
Generation of a-synuclein, g-synuclein, and a-synuclein/g-
synuclein double null mutant mice on C57Bl6J (Charles River)
background was described previously (Abeliovich et al., 2000;
Ninkina et al., 2003; Robertson et al., 2004). Heterozygous b-syn-
uclein null mutant mice (Chandra et al., 2004) on C57Bl6J back-
ground were further backcrossed with C57Bl6J (Charles River) mice
for 6 generations in the Cardiff University Transgenic Animal Unit
before breeding with a-synuclein/g-synuclein double null mutant
mice. Resultant triple heterozygous animals were intercrossed to
produce founders of triple null mutant, double null mutant, and
wild-type colonies used in this study. Thus, all studied animals were
on the same C57Bl6J (Charles River) genetic background. Mice weremaintained in conventional open-lid cages with ad libitum access
to standard chow and water. Mouse genotyping was carried out as
described previously (Chandra et al., 2004; Ninkina et al., 2003;
Robertson et al., 2004). Animals were sacriﬁced by a Schedule 1
method or terminally anesthetized followed by perfusion ﬁxation,
and tissues were collected and coded. Individuals that performed
all further analyses were blinded to the sample genotype. All animal
work was carried out in accordance with the United Kingdom
Animals (Scientiﬁc Procedures) Act (1986).
2.2. Behavioral tests
2.2.1. Inverted grid test
Mice were placed onto a 30 cm by 30 cm squaremesh consisting
of 5-mm squares of 0.5-mm diameter wire. The grid was slowly
rotated to the inverted position and held above a thick layer of
bedding material. If a mouse fell from the grid earlier than the
maximum test time of 1 minute the latency to fall was noted, and
after a 10-minute rest period in the home cage, the test was
repeated. The best result from 3 attempts was included in the
statistics.
2.2.2. Rotarod test
Mice were trained and then tested for 5 minutes on the accel-
erating (4e40 rpm) Ugo Basile 7650 rotarod as described previously
(Robertson et al., 2004). Each mouse was tested 3 times with at
least 30-minute rest period between trials. The mean latency to fall
for these 3 trials was included in the ﬁnal statistics.
2.3. Immunohistochemistry and neuronal cell counts
Mouse brains were collected, ﬁxed with Carnoy’s ﬁxative,
processed, embedded, and cut using an HM 310 microtome
(Microm International). Sections of 8 mm thick were mounted onto
poly-L-lysineecoated slides followed by staining with antibodies
against tyrosine hydroxylase ([TH], mouse monoclonal antibody,
clone TH-2, Sigma) diluted 1:1000. For detection, secondary
biotinylated anti-mouse or anti-rabbit antibodies, Elite plus kits
(Vector laboratories), and 3,3’-diaminobenzidine as chromogen for
the peroxidase reaction were used. The borders of the substantia
nigra and ventral tegmental area (VTA) on these sections were
outlined using distribution atlas of TH-positive cells (Hokfelt et al.,
1984). The number of TH-positive neurons was assessed by
stereological counting as described in our previous publications
(Al-Wandi et al., 2010; Robertson et al., 2004). Brieﬂy, the ﬁrst
section for counting was randomly chosen from the ﬁrst 10 sections
that included SNpc/VTA region. Starting from this section, every
TH-positive cell with a clearly seen nucleus was counted on the
every ﬁfth section through the whole region. The Axiovision
imaging program (Carl Zeiss Vision) was employed to measure
diameters of 30 nuclei of dopaminergic neurons in the SNpc of
every mouse brain included in this study. The nuclei were chosen
randomly and the distance measured as the horizontal length as
they appeared on screen. A mean was calculated for each animal
and used for Abercrombie’s correction (Abercrombie, 1946) to
obtain an actual number of TH positive cells in the structure.
2.4. High-pressure liquid chromography (HPLC) analysis of striatal
neurochemicals
Mouse dorsal striata were dissected, immediately snap-frozen in
liquidnitrogen, andkeptat80 C.Afterextractionwith0.06-MHClO4,
concentrations of striatal dopamine, 3,4-dihydroxyphenylacetic acid
(DOPAC), and homovanillic acid (HVA) were measured by HPLC with
electrochemical detection using a 4.6  150-mm Microsorb C18
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working electrode (Antec Leyden) set atþ0.7 Vwith respect to an Ag/
AgCl reference electrode. Formeasuringdopamineand itsmetabolites,
themobile phase consisted of 12%methanol (v/v), 0.1-Mmonosodium
phosphate, 2.4-mM 1-octane sulphonic acid, 0.68-mM EDTA, pH 3.1.
2.5. Statistical analysis
All data are presented as means  standard error of the mean.
Nonparametric KruskaleWallis analysis of variance with post hoc
WhitneyeMannU-testwasused forassessing statistical signiﬁcanceof
the difference between groups. The c2 test was used for dichotomous
variables (completed or failed the inverted grid test) and Spearman’s
rank test to reveal correlation between various parameters within
groups. Statistical analysis was performed using SPSS/PASW Statistics
versions 16.0 or 18.0 (SPSS, Chicago, IL, USA), GraphPad Prism 4.0
(GraphPad Software, San Diego, CA, USA), and GB-Stat PPC 6.5.4
(Dynamic Microsystems, Inc, Silver Spring, MD, USA).
3. Results
3.1. Mouse welfare and survival rate are not affected by inactivation
of synuclein genes in any possible combination
Experimental cohorts of 7 synuclein-deﬁcient genotypes and
control wild-type male mice were produced on C57Bl6J background
as described in Section 2.1. Most animals in all groups survived up to
the age of 2 years at which stage they were tested, humanely sacri-
ﬁced, and tissues collected for histologic and biochemical
assessments. No signs of neurologic or other speciﬁc health problems
were observed in any of the studied cohorts, and some early casu-
altieswerecausedbyrandomeventsandnot correlatedwithanimals’
genotypes. Statistical analysis of the animal life span censored at
2 years demonstrated no difference between groups (Fig. 1).
3.2. Compromised motor performance of aged mice lacking
b-synuclein
At the ageof 2 years,motor performance of synuclein nullmutant
and control mice was tested in 2 experimental paradigms. The
inverted grid test was used to assess coordination and grip strength,
with accelerated rotarod test used to evaluate sensorimotor func-
tion, coordination, and endurance. Animals lacking b-synuclein,Fig. 1. Normal life span of synuclein null mutant mice. KaplaneMeier survival plot
demonstrates survival rate up to the age of 2 years in cohorts of wild-type mice and
mice carrying homozygous synuclein null alleles in any of 7 possible combinations. Log
rank and generalized Wilcoxon tests for equality of survival did not reveal signiﬁcant
difference between any of studied animal groups (p > 0.05). The number of animals
in groups: 35 (aþbþgþ), 23 (abþgþ), 21 (aþbgþ), 33 (aþbþg), 29 (abþg),
39 (aþbg), 34 (abgþ), and 28 (abg).either singularly or in combinationwith any other member(s) of the
family, on average stayed on the inverted grid for a signiﬁcantly
shorter time than wild-type mice, whereas animals expressing
b-synucleinwere indistinguishable fromwild-typemice evenwhen
lacking any or all other synucleins (Fig. 2). Moreover, only in groups
of mice homozygous for inactivated b-synuclein gene was the
success rate at the inverted grid test signiﬁcantly decreased
compared with the wild-type group (Fig. 2, c2 p value <0.05).
Consistently, mice lacking b-synuclein gene performed signiﬁcantly
worse than wild-type mice in the accelerated rotarod test, whereas
the results for mice with intact b-synuclein alleles were not signiﬁ-
cantly different from the results for wild-type animals (Fig. 3).3.3. Reduced dopamine content in the dorsal striatum of aged mice
lacking a-synuclein
To test if attenuated motor performance of aged synuclein-
deﬁcient mice correlates with changes in the nigrostriatal dopami-
nergic system, levels of dopamine and its major metabolites, DOPAC,
and HVAwere measured in extracts of the dorsal striatum of 2-year-
old mice using HPLC with electrochemical detection. A statistically
signiﬁcant reduction in the striatal dopamine level comparedwith its
level in the aged wild-type animals was observed in all groups of
aged mice lacking a-synuclein, but this level was unaffected in aged
animals lacking other members of the family as long as a-synuclein
remained present (Fig. 4). Moreover, there was no statistically
signiﬁcant difference in the striatal dopamine levels between mice
that lacked only a-synuclein and those additionally lacking either
b- or g-synuclein. However, deletion of all 3 synucleins did lead to a
further reduction (Fig. 4). No statistically signiﬁcant difference in
levels of DOPAC and HVAwas found between the studied groups, but
the ratios of metabolites to dopamine, which are indicators of
dopamine turnover, were signiﬁcantly increased in agedmice lacking
all 3 synucleins. In contrast, DOPAC to dopamine ratio was decreased
in the striatum of mice lacking a- and b-synuclein (Table 1).3.4. No age-dependent loss of dopaminergic neurons in the SNpc of
synuclein-deﬁcient mice
The number of TH-positive neurons was stereologically counted
in the SNpc of aged synuclein-deﬁcient mice. Consistent withFig. 2. Animal performance on the inverted grid test. Animals were tested as described
in Section 2.2.1. The bar chart shows means  standard error of the mean of latency to
fall for groups of 2-year-old wild-type and various synuclein knockout mice. Asterisks
denote statistically signiﬁcant difference between knockout and wild-type groups
(**p < 0.01, KruskaleWallis analysis of variance with post hoc ManneWhitney test).
For each group, the number of animals tested and, in parentheses, stayed on the grid
for the whole 60-second test in at least 1 of 3 trials is shown at the bottom of the
corresponding bar.
Fig. 3. Animal performance on the accelerating rotarod test. Animals were tested as
described in Section 2.2.2. The bar chart shows means  standard error of the mean of
latency to fall for groups of 2-year-old wild-type and various synuclein knockout mice.
Asterisks denote statistically signiﬁcant difference between knockout and wild-type
groups (*p < 0.05, **p < 0.01, KruskaleWallis analysis of variance with post hoc
ManneWhitney test). The number of animals tested for each group is shown at the
bottom of the corresponding bar.
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number of these neurons were observed in single a-synuclein,
single g-synuclein, and a-synuclein/g-synuclein double null
mutant mice when compared with 2-year-old wild-type mice
(Fig. 5), but degrees of these reductions were not greater than those
in young adult mice of the same genotypes, suggesting that there is
no further loss of dopaminergic neurons in aging synuclein-
deﬁcient mice. Similar decreased number of neurons was found
in mice deﬁcient for a- and b-synuclein, but the number of
TH-positive neurons in the substantia nigra of 2-year-old triple
synuclein null mutant mice was the same as that in age-matched
wild-type mice (Fig. 5).
Wedid not reveal statistically signiﬁcant correlation between the
deﬁciency of SNpc dopaminergic neurons and the late-onset
decrease of striatal dopamine content or animal performance in
the accelerated rotarod test. The absolute value for Spearman’s rank
correlation coefﬁcient (rho) was less than 0.5 for all groups with
exceptionof the groupof beta-synuclein nullmutant animals,where
the rho value was 0.6 for number of cells versus dopamine content,
but this correlation was still not statistically signiﬁcant (p > 0.05).Fig. 4. Dopamine levels in the dorsal striatum of 2-year-old synuclein knockout mice.
Dopamine concentrations (in nanograms per milligram of protein) were normalized to
the mean value for wild-type animals (100%). The bar chart shows means  standard
error of the mean data obtained from the number of samples shown at the bottom of
the corresponding bar. A statistically signiﬁcant difference between knockout and
wild-type groups is denoted by asterisks (*p < 0.05, **p < 0.01, KruskaleWallis analysis
of variance with post hoc ManneWhitney test) and between a-synuclein and a/b/g-
synuclein knockout groupseby hash (#p < 0.05).4. Discussion
In the present study, cohorts of aged wild-type mice and null
mutant mice bearing inactivating mutations of the synuclein genes,
all sharing the same C57Bl6 genetic background were produced
within a single breeding programme, and several experimental
paradigms were used to assess the role of synucleins in mainte-
nance of the normal nigrostriatal system function in the aging
brain. This approach allowed minimizing possible effects of inde-
terminate genetic and environmental factors whenmice expressing
different combinations of endogenous synucleins were compared.
Several conclusions could be drawn from the results of these
experiments.
First, we explicitly demonstrated that at least in the unde-
manding laboratory environment, mice do not require synucleins
for executing major physiological processes even at an old age.
Animals of all single and double synuclein null mutant genotypes
were born at the expected Mendelian frequencies, were fertile, did
not display any obvious morphologic or behavioral abnormalities,
and no link was found between the absence of synuclein(s) and the
life span of animals. These observations are consistent with previ-
ous reports from several laboratories that studied single or double
synuclein null mutant mice (Abeliovich et al., 2000; Anwar et al.,
2011; Cabin et al., 2002; Chandra et al., 2004; Dauer et al., 2002;
Ninkina et al., 2003; Robertson et al., 2004; Schluter et al., 2003).
Moreover, although triple synuclein null mutant mice maintained
on a mixed genetic background developed clearly evident neuro-
logical phenotype (e.g., pronounced clasping reﬂex) at old age and
had signiﬁcantly reduced average life span (Burre et al., 2010), in
our cohorts maintained on C57Bl6 background, triple synuclein null
mutant mice had the same life span as wild-type mice and
displayed no readily recognizable signs of neurological problems
even at the age of 2 years. This suggests that certain unidentiﬁed
factors can cooperate with the synuclein deﬁciency in triggering
pathologic changes in the aging nervous system. Consequently,
synucleins can be considered as factors increasing the robustness of
animals and in particular, their nervous systems, to various chal-
lenges they might face in old age.
This notion is supported by subtle (subthreshold for causing
changes in general animal physiology) but statistically signiﬁcant
changes of certain parameters revealed in our experiments
focused on the nigrostriatal system in aging mice. The loss of
dopaminergic neurons was observed in the SNpc of a-, g-, a/g-,
and a/b-synuclein null mutant mice, but it was not progressive
because the reduction in number of these neurons found in aged
animals was not greater than the reduction seen in young animals
of the same genotype (Garcia-Reitboeck et al., 2013; Robertson
et al., 2004), indicating its developmental origin. Interestingly,
animals lacking all 3 synuclein retain full complement of dopa-
minergic neurons in their SNpc. To explain this phenomenon,
molecular mechanisms should be revealed that switch on during
development of dopaminergic neurons only in response to com-
plete absence of synucleins. It is feasible that activation of these
mechanisms secures efﬁcient survival of SNpc neurons during
critical developmental periods.
A signiﬁcant, w20%e30%, dopamine loss was found in the
striatum of 2-year-old mutant mice lacking a-synuclein either
singularly or in combination with other synucleins (i.e., in a-, a/g-,
a/b-, and a/b/g-synuclein null mutant mice) but not in mice
expressing this protein, independently of the presence of other
synucleins. Moreover, additional depletion of other members of
the family, either b- or g-synuclein, did not have an additive effect
on the loss of striatal dopamine seen in a-synuclein depleted
brains, whereas depletion of all 3 family members produced such
effect. These observations indicate that only a-synuclein is vital for
Table 1
Ratios of metabolites to dopamine contents in the striatum of synuclein null mutant mice
Genotype aþ/bþ/gþ a/bþ/gþ aþ/b/gþ aþ/bþ/g a/bþ/g aþ/b/g a/b/gþ a/b/g
DOPAC:DA
Average 0.1019 0.1044 0.0940 0.0981 0.1150 0.0893 0.0807* 0.1608**
SEM 0.0062 0.0046 0.0047 0.0072 0.0043 0.0051 0.0053 0.0091
HVA:DA
Average 0.0827 0.0814 0.0908 0.0832 0.0969 0.0911 0.0980 0.1090*
SEM 0.0136 0.0059 0.0033 0.0059 0.0058 0.0080 0.0060 0.0026
*p < 0.05 and **p < 0.01 between knockout and wild-type groups, ManneWhitney test.
Key: DA, dopamine; DOPAC, 3,4-dihydroxyphenylacetic acid; HVA, homovanillic acid; SEM, standard error of the mean.
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system of aged mice, whereas other 2 synucleins are also involved
in this process, but their inﬂuence is marginal. Results obtained in
previously published studies are consistent with these conclu-
sions. No statistically signiﬁcant loss of dopamine has been
detected in the striatum of young adult (4 to 6-month old) a-, g-,
and a/g-synuclein null mutant mice (Robertson et al., 2004).
Therefore, striatal dopamine deﬁciency in a- and a/g-synuclein
null mutant mice observed in the present study is an age-related
phenotype. However, in the striatum of young adult a/b- and a/
b/g-synuclein null mutant mice, dopamine loss comparable to that
observed in aged mice has been reported (Anwar et al., 2011;
Chandra et al., 2004). Because even aged b/g-synuclein null
mutant mice do not display decreased striatal dopamine content,
it is feasible to suggest that a-synuclein is the most efﬁcient of 3
family members in maintaining normal level of this neurotrans-
mitter, b-synuclein is less efﬁcient as it is able to compensate for a-
synuclein loss in young but not in aged animals, and g-synucleinFig. 5. The number of dopaminergic neurons in the substantia nigra pars compacta
(SNpc) of 2-year-old wild-type and various synuclein knockout mice. (A) The bar chart
shows means  standard error of the mean of stereologically counted TH-positive
neurons per hemisphere. Asterisks denote statistically signiﬁcant difference between
knockout and wild-type groups (*p < 0.05, **p < 0.01, KruskaleWallis analysis of
variance with post hoc ManneWhitney test). The number of samples processed for
each group is shown at the bottom of the corresponding bar. (B) Representative images
of anti-TH immunostained sections through the midbrain of the wild-type and synu-
clein deﬁcient mice at the level between Bregma 3.0 to 3.2, where the border be-
tween SNpc and ventral tegmental area is well deﬁned. Insets show SNpc
dopaminergic neurons at higher magniﬁcation.does not play signiﬁcant role in maintaining striatal dopamine
level.
An incomplete overlap between synuclein null mutations
causing the loss of dopaminergic neurons and causing striatal
dopamine depletion as well as the absence of statistically signiﬁ-
cant correlation between these 2 parameters suggests an inde-
pendent nature of these events in the brain of synuclein-deﬁcient
mice.
The increased metabolites to dopamine ratios (DOPAC:dop-
amine and HVA:dopamine) detected only in triple synuclein null
mutant mice might imply that certain mechanisms compensating
for reduced striatal dopamine levels by increasing turnover of this
neurotransmitter become activated only when the interfamily
functional redundancy cannot be employed.
The observed degree of striatal dopamine depletion was too
small to cause a motor phenotype, which is commonly associ-
ated with the drop of dopamine content below 30% of the level
in the striatum of healthy animals. However, we found that
balance and coordination was compromised in several lines of
aged synuclein null mutant mice, although this set of genotypes
did not fully overlap with either a set displaying deﬁciency in
the number of SNpc dopamine neurons or a set with depleted
striatal dopamine content. A substantial decline of both inverted
grid and rotarod performance was observed for all groups of
animals lacking b-synuclein, that is, b-, b/g-, a/b-, and a/b/g-
synuclein null mutant mice and once again, depletion of other
synucleins had no additive effect. This suggests that the effect of
b-synuclein deﬁciency on the motor performance of aged ani-
mals cannot be compensated by other members of the family.
Because b-synuclein is highly expressed in many populations of
brain neurons, it cannot be ruled out that compromised balance
and coordination of animals lacking this protein is due to an
improper function of not only their nigrostriatal system but also
other neuronal systems involved in regulation of motor
functions.
A functional redundancy within the synuclein family has been
suggested based on a high degree of similarity between the family
members. However, results of our studies suggest that each synu-
clein has a distinct set of functions, these 3 sets do not completely
overlap and therefore, the loss of only some functions can be
compensated by other family members, whereas the loss of other
function can be aggravated by the absence of other family
members. Still sufﬁcient in a fully adept nervous system, this
incomplete compensation can cause functional deﬁciencies in
combinationwith certain other events that on their own have no or
only subtle detrimental effect on the nervous system function. As a
gradual accumulation of such subtle functional defects is a common
trait in the aging nervous system, an impact of the loss of a synu-
clein function becomes particularly detrimental for aged animals.
This might be relevant to certain neurodegenerative conditions
characterized by the depletion of a functional pool of particular
synuclein due to its intensive aggregation and trapping in patho-
logic inclusions.
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